Ethylene Diamine Tetraacetic Acid (EDTA)

(Ship Cold) Nasal Spray

0.25% (0.25 mg/Spray)  |  0.5% (0.5 mg/Spray)

Ready to prescribe?
Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Ethylenediaminetetraacetic Acid Description1,2  

EDTA has multiple medicinal uses. It functions as a chelating agent for high calcium levels and exposure to heavy metals, including lead. It also acts as an anticoagulant in laboratory hematology tests. Furthermore, EDTA can be applied to help reduce microbial growth in central venous lines as a lock solution and to interfere with biofilm formation by certain bacterial pathogens, including those linked to chronic rhinosinusitis. When used as a nasal spray, EDTA has been examined for its effects on biofilms produced by bacteria such as S. aureus (including methicillin-resistant strains), P. aeruginosa, E. coli, K. pneumoniae, Serratia marcescens, as well as fungi like Candida albicans and Candida glabrata, and may support the activity of antimicrobial agents.

Mechanism of Action1,2

EDTA works on sinus infections by weakening the extracellular matrix of the biofilm by sequestering the cations (calcium, magnesium, and zinc) required to maintain the structure of the biofilm. Once the biofilm is destabilized the immune system and antimicrobials can better work to treat the infection.

Common1,2   

  • Rash and a histamine-like reaction consisting of headache, sneezing, nasal congestion, and lacrimation

Contraindications1,2

  • Hypersensitivity or intolerance to EDTA or excipients
  • Patients with hepatitis
  • Systematic administration not recommended during pregnancy—check with health care provider about effects during pregnancy

Precautions1,2

  • Caution in patients with renal dysfunction
  • Store at 2°C–8°C (36°F–46°F)
  • Protect from light, heat, and moisture
  1. Clinical Pharmacology EDTA clinical monograph 2025 https://www.clinicalkey.com/pharmacology/ 
  2. Hale SJM, Wagner Mackenzie B, Lux CA, Biswas K, Kim R, Douglas RG. Topical Antibiofilm Agents With Potential Utility in the Treatment of Chronic Rhinosinusitis: A Narrative Review. Front Pharmacol. 2022 Jun 13;13:840323.

WPPL operates as a 503A compounding pharmacy and prepares individualized prescription medications pursuant to provider direction. Compounded preparations are not reviewed, tested, or approved by the FDA.

This listing also includes commercially manufactured products for convenience; these items are not compounded by our pharmacy and are sold as provided by their manufacturers. Actual products in stock at time of dispensing may vary due to supply chain variability. Any statements regarding non-compounded products are manufacturer-supplied, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease. WPPL does not verify or endorse any therapeutic claims made by manufacturers. Please refer to original labeling for complete product information.

EXPLORE MORE

Related Medications

Licensed to ship across the U.S.

Your orders arrive promptly and privately, delivered directly to your door.

Providers: Let’s Partner for Better Patient Care

If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.

To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com

New providers setup / update an existing account:
newaccounts@wppharmalabs.com